A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Neutropenia|Febrile Neutropenia
Interventions: DRUG: Pegylated rhG-CSF 100μg/kg|DRUG: Pegylated rhG-CSF:150 μg/kg|DRUG: rhG-CSF 5 μg/kg/day
Sponsor: Jiangsu HengRui Medicine Co., Ltd.